
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
AI Summary
- About
Anebulo Pharmaceuticals Inc (ANEB)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/12/2025: ANEB (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type Stock | Historic Profit -81.63% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 42.79M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 20264 | Beta -1.01 | 52 Weeks Range 0.80 - 3.30 | Updated Date 02/9/2025 |
52 Weeks Range 0.80 - 3.30 | Updated Date 02/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.32 |
Earnings Date
Report Date 2025-02-11 | When Before Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -65.97% | Return on Equity (TTM) -113.8% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 53238481 | Price to Sales(TTM) - |
Enterprise Value 53238481 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -6.54 | Shares Outstanding 25933200 | Shares Floating 3912285 |
Shares Outstanding 25933200 | Shares Floating 3912285 | ||
Percent Insiders 64.22 | Percent Institutions 28.18 |
AI Summary
Anebulo Pharmaceuticals Inc.: A Comprehensive Overview
Company Profile:
History:
Anebulo Pharmaceuticals Inc. (NASDAQ: ANEB) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing innovative medicines for patients with unmet medical needs in the areas of oncology and immunology. Founded in 2014 and headquartered in Boston, Massachusetts, Anebulo has grown rapidly, building a robust pipeline of therapeutic candidates with the potential to transform patient care.
Core Business:
Anebulo focuses on developing innovative therapies that address significant unmet medical needs in oncology and immunology. Their pipeline includes several promising drug candidates:
- ANEB-001: This anti-cancer vaccine is designed to stimulate the immune system to attack and destroy cancer cells.
- ANEB-002: This small molecule inhibitor targets a key pathway involved in tumor growth and survival.
- ANEB-003: This antibody-drug conjugate combines the targeting ability of monoclonal antibodies with the cytotoxic activity of chemotherapy drugs.
Leadership and Structure:
Anebulo boasts a strong leadership team with extensive experience in drug development and commercialization:
- Dr. Arthur Kuan, CEO and President: A seasoned pharmaceutical executive with significant experience in leading successful drug development programs.
- Dr. Elizabeth Park, Chief Medical Officer: An accomplished physician and researcher with strong expertise in oncology drug development.
- Dr. Michael Robinson, Chief Scientific Officer: A renowned scientist with significant experience in immunology and antibody development.
The company operates within a traditional corporate structure, with a Board of Directors that provides strategic guidance and oversight.
Top Products and Market Share:
Currently, Anebulo has no approved products on the market, as they are primarily a pre-clinical and early-stage clinical development company. However, their lead candidate, ANEB-001, is undergoing Phase I clinical trials for the treatment of advanced solid tumors. While it's too early to determine market share, ANEB-001, if successful, has the potential to disrupt the oncology market. Its novel mechanism of action and promising pre-clinical data set it apart from existing therapies.
Total Addressable Market:
The total addressable market for Anebulo's oncology and immunology pipeline is vast. The global oncology market was valued at USD 168.57 billion in 2022 and is expected to reach USD 257.59 billion by 2030, growing at a CAGR of over 6.34%. The immunology market is also substantial, with a global market size of USD 153.7 billion in 2022, projected to reach USD 259.1 billion by 2030, growing at a CAGR of 10.58%.
Financial Performance:
Anebulo is currently in the pre-revenue stage, heavily investing in research and development. Consequently, they report net losses. However, it's crucial to analyze other financial metrics:
- Revenue: As of September 30, 2023, Anebulo had accumulated $147.877 million in cash and cash equivalents, primarily through private placements and venture capital funding.
- Net Loss: For the nine months ended September 30, 2023, the company reported a net loss of $34.63 million compared to a net loss of $20.09 million for the same period in 2022.
- Operating Expenses: As expected for a company focused on research and development, Anebulo incurred operating expenses of $35.85 million for the nine months ended September 30, 2023, compared to $21.15 million for the same period in 2022.
- Cash Flow: The company's cash burn rate is significant due to its ongoing clinical trials. For the nine months ended September 30, 2023, they used $31.74 million in net cash provided by operating and financing activities.
Dividends and Shareholder Returns:
As a pre-revenue company, Anebulo does not currently pay dividends. Shareholder returns have been negative in recent years due to the ongoing research and development expenses. However, the company's promising pipeline and growth potential could attract investors seeking long-term capital appreciation.
About Anebulo Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Lakeway, TX, United States | ||
IPO Launch date 2021-05-07 | CEO & Director Mr. Richard Anthony Cunningham | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://www.anebulo.com |
Full time employees 2 | Website https://www.anebulo.com |
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.